Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients
Tóm tắt
A pharmacokinetic study after a single dose of ceftriaxone, cefoxitin, cefuroxime and ceftazidime was performed to investigate the influence of protein binding and severity of disease on the renal elimination. In intensive-care patients drug-protein binding was substantially less compared to that in volunteers and patients with less complicated diseases. This did not result in increased elimination but, due to increased apparent volumes of distribution, prolonged half-life times were observed. Consequently, in patients with complicated disease states a dosage regimen should be based on pharmacokinetic studies performed in a similar patient group.
Tài liệu tham khảo
Tillement JP, Lhoste F, Giudicelli JF. Diseases and drug protein binding. Clin Pharmacokinet 1978;3:144–54.
Lindup WE, L'eorme MC. Plasma protein binding of drugs. Br Med J 1981;282:212–4.
Svensson CK, Woodruff MN, Baxter JG, Lalka D. Free drug concentration monitoring in clinical practice. Rationale and current status. Clin Pharmacokinet 1986;11:450–69.
Rowland M. Protein binding and drug clearance. Clin Pharmacokinet 1984;9(suppl 1):10–7.
Wise R. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet 1986;11:470–82.
Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH. Effects of concentrationdependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther 1981;29:650–7.
Brogden RN, Heel RC, Speight TM, Avery GS. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 1979; 17:1–37.
Foord RD. Cefuroxime: Human pharmacokinetics. Antimicrob Agents Chemother 1976;9:741–7.
Harding SM, Monro AJ, Thornton JE, Ayrton J, Hogg MIJ. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. J Antimicrob Chemother 1981;8(suppl B):263–72.
Metzler CM, Elfring GL, McEwen AJ. A package of computer programs for pharmacokinetic modeling. Biometrics 1974;30:562–3.
Greenblatt DJ, Koch-Weser J. Clinical pharmacokinetics. 1. N Engl J Med 1975;293:702–5.
Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ. Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults. Antimicrob Agents Chemother 1982;22:816–23.
Patel IH, Kaplan SA. Pharmacokinetic profile of ceftriaxone in man. Am J Med 1984;77(suppl4C):17–25.
Scully BE, Fu KP, Neu HC. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. Am J Med 1984;77(suppl4C):112–6.
Joos B, Luethy R, Muehlen E, Siegenthaler W. Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections. Am J Med 1984;77(suppl4C):59–62.
Patel IH, Sugihara JG, Wėinfeld RE, Wong EGC, Siemsen AW, Berman SJ. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 1984;25:438–42.
Ti T-Y, Fortin L, Kreeft JH, East DS, Ogilvie RJ, Somerville PJ. Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agents Chemother 1984;25:83–7.
Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E. Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther 1983;33:633–41.
Cohen D, Appel GB, Scully B, Neu HC. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob Agents Chemother 1983;24:529–32.
Van Dalen R, Vree TB, Baars AM, Termond ESF. Dosage adjustment for ceftazidime in patients with impaired renal function. Eur J Clin Pharmacol 1986;30:597–605.